Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.24.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating Activities:      
Net loss $ (29,815) $ (42,350) $ (33,152)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization [note 5] 228 236 250
Stock-based compensation [note 11[c], note 11[d] and note 11[e]] 3,439 3,270 2,187
Shares issued as settlement with trade vendor 273 26 41
Accrued interest on SVB convertible debt [note 9] 1,216 1,170  
Accretion of discount on modification of debt 430    
Contigent consideration [note 6 and note 7] 528    
Changes in operating assets and liabilities:      
Grant receivable [note 4] (6) 48 (153)
Prepaid expenses and other assets 1,176 (931) (228)
Accounts payable (1,042) 799 509
Accrued liabilities other (32) 55 (245)
Accrued clinical liabilities (1,449) 376 899
Accrued compensation 633 (263) 466
Lease obligation (58) (5) (14)
Net cash used in operating activities (24,479) (37,569) (29,440)
Financing Activities:      
Proceeds from exercise of warrants [note 11[g]] 227 24 338
Receipt of convertible debt from SVB [note 9]     14,929
Proceeds from ATM, net of issuance costs [note 11[b]]   1,330  
Proceeds from employee stock purchase plan [note 11[e]]   126  
Taxes paid related to net share settlement of equity awards (220) (47)  
Net cash provided by financing activities 15,278 19,315 36,610
Investing Activities:      
Purchase of property and equipment (21)    
Net cash provided by (used in) investing activities (21)    
Effect of exchange rate changes on cash (3) 3 (1)
Net increase (decrease) in cash, cash equivalents and restricted cash (9,225) (18,251) 7,169
Cash, cash equivalents and restricted cash at beginning of year 24,821 43,072 35,903
Cash, cash equivalents and restricted cash at end of year 15,596 24,821 43,072
May 2021 Public Offering [Member]      
Financing Activities:      
Proceeds from offering, net of issuance costs [note 11[b]]     $ 21,343
November 2022 Private Placement [Member]      
Financing Activities:      
Proceeds from private placement, net of issuance costs [note 11[b]] (30) $ 17,882  
May 2023 Private Placement [Member]      
Financing Activities:      
Proceeds from private placement, net of issuance costs [note 11[b]] $ 15,301